 NOVATO, Calif., Sept. 27, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that new data highlighting Crysvita burosumab-twza for the treatment of X-linked hypophosphatemia XLH and UX143 setrusumab for the treatment of osteogenesis imperfecta OI will be presented at the American Society for Bone and Mineral Research ASBMR 2021 Annual Meeting. The meeting will take place October 1-4 in-person in San Diego with programming also virtually accessible in real-time. 